文献速递炎症性肠病

长期口服万古霉素治疗炎症性肠病患者艰难梭菌感染与低复发率相关

Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence.
PubMed 文献 · Am J Gastroenterol · 2019-01-01

本研究比较炎症性肠病(IBD)患者接受长期(21-42天)与短期(10-14天)口服万古霉素治疗艰难梭菌感染(CDI)后的复发和再感染率。结果显示长期治疗组CDI复发率为1.8%,显著低于短期治疗组的11.7%(OR=0.13,P=0.043),再感染率无显著差异。多因素分析显示长期治疗与更低复发风险独立相关(OR=0.03,P=0.021)。

要点

  • 长期口服万古霉素(21-42天)较短期(10-14天)显著降低IBD患者CDI复发率。
  • 长期与短期治疗在CDI再感染率上无显著差异。
  • 多因素分析支持长期万古霉素治疗与更低复发风险独立相关。

核心结论

  • 长期口服万古霉素治疗与IBD患者CDI复发率降低相关。

主要发现

  • 长期万古霉素组CDI复发率为1.8%,短期组为11.7%(OR=0.13,P=0.043)。
  • CDI再感染率长期组14.0% vs 短期组16.9%,无显著差异(P=NS)。
  • 多因素logistic回归显示长期万古霉素治疗较短期治疗复发风险更低(OR=0.03,P=0.021)。

临床怎么用

  • 对于IBD合并CDI的患者,可考虑延长口服万古霉素疗程至21-42天以降低复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients with inflammatory bowel disease (IBD) are susceptible to Clostridioides difficile infections (CDIs), suffering from greater morbidity and mortality than the general population. Previous studies have proven the efficacy of oral vancomycin therapy in CDI, but there are no definitive guidelines to treat patients with IBD. We assessed the relationship between the length of vancomycin therapy and rates of CDI recurrence and reinfection in patients with IBD. METHODS: We compared rates of CDI recurrence and reinfection in Crohn's disease and ulcerative colitis (UC) patients receiving long-duration (LD) and short-duration (SD) oral vancomycin therapy, defined as 21-42 days and 10-14 days, respectively. Recurrence and reinfection were defined as positive C. difficile toxin assay by polymerase chain reaction within 8 weeks of the end of antibiotic therapy and after 8 weeks of the end of antibiotic therapy, respectively. The Fisher exact test was used to test for significance, and multivariate logistic regression models were constructed to control for other covariables. RESULTS: One hundred thirty-four patients with IBD (57 ulcerative colitis and 77 Crohn's disease) met inclusion criteria. LD vancomycin had a 1.8% incidence of CDI recurrence, compared with 11.7% in the SD vancomycin group (odds ratio = 0.13, P = 0.043). CDI reinfection rates and time to reinfection were not significantly different (LD 14.0% vs SD 16.9%, P = NS). Multivariate logistic regression models showed that treatment with LD vancomycin had lower odds for recurrence than SD vancomycin (odds ratio = 0.03, P = 0.021). DISCUSSION: LD vancomycin is associated with lower rates of CDI recurrence compared with SD vancomycin therapy. These results will help guide clinical decisions and the development of a prospective trial.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Lei DK, Ollech JE, Andersen M, et al. Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence. Am J Gastroenterol. 2019. PMID: 31714359. doi:10.14309/ajg.0000000000000460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。